Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) EBT Margin (2016 - 2025)

Amicus Therapeutics' EBT Margin history spans 16 years, with the latest figure at 1.7% for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 360.0% year-over-year to 1.7%, compared with a TTM value of 0.03% through Dec 2025, up 547.0%, and an annual FY2025 reading of 0.03%, up 547.0% over the prior year.
  • EBT Margin for Q4 2025 was 1.7% at Amicus Therapeutics, down from 20.27% in the prior quarter.
  • The five-year high for EBT Margin was 20.27% in Q3 2025, with the low at 103.48% in Q1 2022.
  • Average EBT Margin over 5 years is 40.14%, with a median of 37.65% recorded in 2022.
  • Year-over-year, EBT Margin plummeted -1554bps in 2022 and then surged 5204bps in 2023.
  • Tracing FOLD's EBT Margin over 5 years: stood at 97.74% in 2021, then increased by 19bps to 79.55% in 2022, then surged by 65bps to 27.51% in 2023, then surged by 119bps to 5.3% in 2024, then tumbled by -68bps to 1.7% in 2025.
  • Per Business Quant, the three most recent readings for FOLD's EBT Margin are 1.7% (Q4 2025), 20.27% (Q3 2025), and 12.4% (Q2 2025).